Skip to main content
    Manually curated feed

    UK Peptide Safety Timeline

    Chronological reference of UK and international regulatory updates relevant to peptides and GLP-1 medicines — MHRA alerts, NICE technology appraisals, EMA decisions, WADA Prohibited List changes, DHSC supply guidance. Most-recent first. Manually curated by editors; no scraping, no automated feed.

    MHRA
    2026-02

    Falsified Mounjaro 15 mg KwikPens reaching UK patients

    Public-health alert about counterfeit tirzepatide pens obtained via unlicensed online supply. Patients reported unexpected adverse reactions and inconsistent effects consistent with contents not being genuine tirzepatide at the stated concentration.

    MHRA
    2025-12

    Ongoing enforcement against ‘compounded GLP-1’ online supply

    MHRA continues to act against UK online clinics marketing ‘compounded semaglutide’ and ‘compounded tirzepatide’ as cheap Wegovy / Mounjaro alternatives. The legal basis is unlicensed-medicine supply outside the narrow ‘specials’ framework.

    NICE
    2024-12

    TA1026 published — tirzepatide for managing overweight and obesity

    NICE recommends tirzepatide (Mounjaro) on the NHS for weight management with BMI ≥35 kg/m² and at least one weight-related condition; lower BMI thresholds apply for some ethnic backgrounds. Roll-out is phased through specialist weight-management services and primary-care pathways.

    MHRA
    2024

    Counterfeit Ozempic — sustained enforcement

    Counterfeit Ozempic shipments continue to be intercepted at the UK border. Pattern includes pens repackaged into non-Novo cartons, missing or wrong-language PILs, and (in some cases) insulin substitution that creates acute hypoglycaemia risk in non-diabetic users.

    NICE
    2023-03

    TA875 published — semaglutide for managing overweight and obesity

    NICE recommends semaglutide 2.4 mg (Wegovy) for NHS weight management via specialist services. BMI and comorbidity criteria; lower BMI thresholds for some ethnic backgrounds; two-year duration cap on the recommendation.

    WADA
    Ongoing

    Prohibited List — peptide hormones and growth factors (S2)

    GLP-1 receptor agonists in clinical use, growth-hormone secretagogues (CJC-1295, ipamorelin, sermorelin, tesamorelin), thymosin beta-4 / TB-500, and related substances remain on the WADA Prohibited List under S2 at all times. Other unlicensed research peptides (BPC-157, MOTS-c, melanotan II, retatrutide) fall under S0 (non-approved substances).

    MHRA
    Ongoing

    Melanotan I and II — repeated public-health warnings

    MHRA continues to warn against use of injectable and nasal-spray Melanotan products for cosmetic tanning. Documented adverse effects include mole changes and case reports of subsequent melanoma diagnoses, severe GI effects, and cardiovascular events.

    DHSC
    Ongoing

    GLP-1 supply guidance to NHS prescribers

    Department of Health and Social Care has issued repeated guidance asking clinicians to prioritise Ozempic for type 2 diabetes patients and to direct weight-management cases to Wegovy or Mounjaro, given sustained off-label demand pressure on Ozempic supply.

    Sources we monitor

    Related